UCB S.A.
UCB
Rank in Stocks
#510
UCB S.A., a biopharmaceutical enterprise founded in 1925 and headquartered in... UCB S.A., a biopharmaceutical enterprise founded in 1925 and headquartered in Brussels, Belgium, focuses on developing innovative solutions for individuals living with neurological and immunological diseases. Its diverse commercialized portfolio includes Cimzia, targeting inflammatory TNF-mediated conditions such as Crohn's disease, various forms of spondyloarthritis, rheumatoid arthritis, and psoriasis. For epilepsy management, UCB offers Vimpat, Keppra, and Briviact, along with Nayzilam, an intranasal rescue treatment for seizure clusters. Neupro is available for Parkinson's disease and restless legs syndrome, while Zyrtec and Xyzal address allergy symptoms. Other key products include Evenity for osteoporosis in postmenopausal women, and BIMZELX, which treats psoriasis, psoriatic arthritis, axial spondyloarthritis, and hidradenitis suppurativa. The company also provides dapirolizumab pegol for systemic lupus erythematosus. UCB's robust development pipeline features candidates like rozanolixizumab, aimed at myasthenia gravis, immune thrombocytopenia, and chronic inflammatory demyelinating polyneuropathy; zilucoplan for myasthenia gravis and immune-mediated necrotizing myopathy; staccato alprazolam for prolonged seizures; Bepranemab for Alzheimer's disease; and UCB0599 for Parkinson's disease. Beyond its proprietary drug development, UCB also conducts contract manufacturing. The company engages in significant collaborations with entities such as Amgen, Biogen, Roche/Genentech, Novartis, Otsuka, and doc.ai. UCB's global footprint extends across numerous countries, including the United States, Japan, China, Belgium, and a broad presence throughout Europe, encompassing Germany, Spain, France, Italy, the United Kingdom, and Ireland.
Share Price
$248.03
Market Cap
$47.29B
Change (1 day)
1.90%
Change (1 year)
-15.90%
Country
BE
Trade UCB S.A. (UCB)
Category
Healthcare
Revenue for UCB S.A. (UCB)
Revenue in Jun 2026 TTM: $10.11B
According to UCB S.A. latest financial reports the company's current revenue (TTM) is $10.11B. In 2023 the company made a revenue of $5.81B a decrease compared to the revenue in the year 2022 that was $5.92B. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for UCB S.A. from 2002 to 2026
Revenue at the end of each year
| Year | Revenue | Change |
|---|---|---|
| 2026 (TTM) | $10.11B | 57.94% |
| 2024 | $6.40B | 10.26% |
| 2023 | $5.81B | -1.89% |
| 2022 | $5.92B | -9.92% |
| 2021 | $6.57B | 0.88% |
| 2020 | $6.51B | 18.13% |
| 2019 | $5.51B | 3.56% |
| 2018 | $5.32B | -0.85% |
| 2017 | $5.37B | 23.03% |
| 2016 | $4.36B | 3.68% |
| 2015 | $4.21B | 4.02% |
| 2014 | $4.05B | -6.09% |
| 2013 | $4.31B | -5.66% |
| 2012 | $4.57B | 8.68% |
| 2011 | $4.20B | -2.33% |
| 2010 | $4.30B | -3.70% |
| 2009 | $4.47B | -10.97% |
| 2008 | $5.02B | -5.32% |
| 2007 | $5.30B | 59.66% |
| 2006 | $3.32B | 20.02% |
| 2005 | $2.77B | -42.28% |
| 2004 | $4.79B | 14.36% |
| 2003 | $4.19B | -29.19% |
| 2002 | $5.92B | 0.00% |
Revenue for similar companies or competitors
| Company | Revenue | Revenue Difference | Country |
|---|---|---|---|
| $12.62B | 24.86% |
US
|
|
| $2.23B | -77.96% |
US
|
|
| $15.74B | 55.72% |
AU
|
|
| - | - |
CH
|
|
| $6.02B | -40.45% |
NL
|
